AlloVir Inc
ALVR
Get informed when a big investor buys or sells
+ FollowMarket Cap$233.45M
Close$
$1.02
89.6% downside
Current Fair Value
89.6% downsideOvervalued by 89.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $233.45 Million |
|---|---|
| Enterprise Value | $140.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.85 |
| Beta | 0.62 |
| Outstanding Shares | 23,797,306 |
Return
| Return on Equity | -76.75% |
|---|---|
| Return on Assets | -44.47% |
| Return on Invested Capital | -52.60% |
Valuation & Multiples
| P/E Ratio | -1.17 |
|---|---|
| PEG | -80.37 |
| Price to Sales | - |
| Price to Book Ratio | 4.91 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.87 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kalaris Therapeutics Inc
14 employees
CEO: Mr. Andrew Oxtoby Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.